The U.S. Food and Drug Administration (FDA) announced that all GLP-1 medications must include warnings about a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to sudden vision loss.
Although a direct causal link has not been established, the FDA's decision follows a review of clinical trials and real-world data, which indicated a higher incidence of NAION among GLP-1 users—6.4 cases per 100,000 patient-years compared to 3.8 for other treatments.
Analysts from Citi suggest that while this warning may raise concerns among patients and investors, the rarity of NAION and the substantial benefits of GLP-1 drugs in managing weight, glycemic control, and cardiovascular health will likely mitigate any significant impact on their usage.
Additionally, these drugs already carry strong safety warnings regarding potential thyroid tumors, further complicating their risk profiles. The FDA's action may draw attention but is expected to have limited effects on the overall adoption of GLP-1 therapies